CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$2.32 USD
-0.01 (-0.34%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $2.20 -0.12 (-5.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for CanFite Biopharma Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 1 | 1 | 1 | 2 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 1 | 1 | 1 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 9 | 11 | 14 | 15 | 14 |
Income After Depreciation & Amortization | -8 | -10 | -13 | -14 | -12 |
Non-Operating Income | 1 | 0 | 0 | 0 | 3 |
Interest Expense | 0 | 0 | 0 | 0 | 1 |
Pretax Income | -8 | -10 | -13 | -14 | -10 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -8 | -10 | -13 | -14 | -10 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -8 | -10 | -13 | -14 | -10 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -8 | -10 | -13 | -14 | -12 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -8 | -10 | -13 | -14 | -12 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.26 | 2.72 | 1.84 | 1.20 | 0.29 |
Diluted EPS Before Non-Recurring Items | -1.79 | -3.74 | -6.80 | -12.00 | -33.00 |
Diluted Net EPS (GAAP) | -3.00 | -3.00 | -9.00 | -12.00 | -33.00 |
Fiscal Year end for CanFite Biopharma Ltd falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | 0.16 | 0.20 | 0.20 |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | -1.65 | -1.76 | -1.67 |
Extras & Discontinued Operations | NA | NA | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | NA | -1.65 | -1.76 | -1.67 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 5.36 | 4.03 | 4.01 |
Diluted EPS Before Non-Recurring Items | -99,999.00 | -99,999.00 | -0.31 | -0.43 | -0.40 |
Diluted Net EPS (GAAP) | -99,999.00 | -99,999.00 | -0.31 | -0.43 | -0.40 |